ALK Gene Mutation Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting alk gene mutation clinical trials across 5 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Changsha, Hunan, China, Meldola, Italy, Florence, Italy. Updated daily from ClinicalTrials.gov.


ALK Gene Mutation Trials at a Glance

7 actively recruiting trials for alk gene mutation are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Changsha, Meldola, and Florence. Lead sponsors running alk gene mutation studies include Hunan Province Tumor Hospital, Centro di Riferimento Oncologico - Aviano, and Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Browse alk gene mutation trials by phase

Treatments under study

About ALK Gene Mutation Clinical Trials

Looking for clinical trials for ALK Gene Mutation? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ALK Gene Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ALK Gene Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Non-small Cell Lung CancerALK Gene MutationEGFR Gene Mutation+3 more
University of Colorado, Denver100 enrolled1 locationNCT03042221
Recruiting
Phase 2

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Non-small Cell Lung CancerALK Gene MutationEGFR Gene Mutation+2 more
Hunan Province Tumor Hospital6,000 enrolled1 locationNCT04322890
Recruiting

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

NSCLC Stage IVALK Gene MutationALK Sensitizing Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS108 enrolled1 locationNCT06234579
Recruiting
Phase 2

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Lung AdenocarcinomaImmunotherapyALK Gene Mutation
Hunan Province Tumor Hospital78 enrolled1 locationNCT05266846
Recruiting
Phase 2

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Non-small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano45 enrolled9 locationsNCT06378892
Recruiting
Not Applicable

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

Radiotherapy Side EffectNon-small Cell Lung CancerALK Gene Mutation
Karolinska University Hospital70 enrolled1 locationNCT05724004